2013 年 39 巻 6 号 p. 381-387
Dacarbazine (DTIC) produces adverse reactions including local venous pain during the intravenous injection. DTIC is reported to be photolyzed to produce certain kinds of pain producing substances. 5-diazoimidazole-4-carboxamide (Diazo-IC) is considered to be a causative photolyte of venous pain. A newly designed cover shield has been used at Osaka University Hospital when DTIC is administered for the last 4 years. This shield comprises black cotton and covers both the infusion bag and route of infusion. We evaluated the effectiveness of this new shield against photodegradation of DTIC by determining the concentration of Diazo-IC. DTIC was dissolved with an injection solvent and mixed with 5％ dextrose in water. Prepared samples were divided into 3 groups (without shield, infusion bag covered with shield, and infusion bag and infusion route covered with shield) and exposed under natural light conditions indoors. Prepared solutions ran down through the route and those samples were taken before and after passing the route pipe. Diazo-IC in the samples was measured by HPLC. Production of Diazo-IC in the non-covered bag was significantly increased in comparison with that in covered infusion bags. Diazo-IC production in samples after passing through the route was significantly increased compared with that in samples taken before passing through the route of the non-covered shield and covered infusion bag only. For the covered infusion bag and infusion route, the samples taken before and after passing through the route did not show significant differences. These data suggest that the new shield, which almost perfectly covers both the infusion bag and route of infusion, is effective in preventing DTIC photodegradation.